Ulysses G. J. Balis

Ulysses G.J. Balis, MD, Fellow AIMBE is the A. James French Professor of Pathology Informatics at the University of Michigan, with additional roles as Associate Chief Medical Information Officer and Informatics Fellowship Program Director. He also serves as the conference organizer for the annual Pathology Informatics Summit meeting series, as hosted by the Association for Pathology Informatics. Dr. Balis has longstanding interests in digital image analysis, computational pathology, AI-driven workflow, and clinical deployment of digital pathology.

Suzanne M Dintzis

Suzanne M. Dintzis, MD, PhD, FCAP, is a Professor of Laboratory Medicine and Pathology at the University of Washington Medical Center in Seattle. Dr. Dintzis’ clinical areas of focus include breast and gynecologic pathology. She is currently engaged in breast cancer research, improvements in digital microscopy, and exploring the interfaces between quality of care and communication. Dr. Dintzis is the immediate past President of the Washington State Society of Pathologists, Chair of the Washington State delegation to the College of American Pathologists House of Delegates, and a Board member of the Digital Pathology Association.

Jason Hipp

Dr. Jason Hipp, MD/PhD is the Chief Digital Innovation Officer for Mayo Collaborative Services (the commercial diagnostics arm of Mayo Clinic) and the Medical Director for Biopharma Diagnostics.  He completed his undergraduate training at UCSD, his MD/PhD at Wake Forest University, residency in pathology at the NIH, and fellowship training in Informatics at the University of Michigan.  He is a board-certified pathologist who has been active in the field of digital pathology, AI and cancer research.  He spent most of hist time in Industry, having worked at Novartis, BMS and AstraZeneca.  He was also the first pathologist hired by Alphabet and was the lead pathologist at Google.  He spent two years before his current role involved in Mayo Clinic’s Practice, where he was the founder and Chair of the Division of Computational Pathology & Artificial Intelligence.

Savitri Krishnamurthy

Dr. Krishnamurthy is a Professor of Pathology at The University of Texas MD Anderson Cancer Center in Houston, TX. Her areas of expertise include Breast Pathology and Cytopathology. She is a nationally and internationally recognized Breast Pathologist and Cytopathologist who has contributed significantly towards patient care, education and clinical translational research. She is committed towards advancing our understanding of the biology and management of breast cancer and has several contributions related to clinical research, genomics and proteomics of breast cancer. In recent years, she has been an avid researcher and leading investigator for the investigation of optical imaging modalities in pathology, digital and computational pathology studies which are predicted to make revolutionary changes to the field of Anatomic Pathology. She has been included in the “Best Doctors of America” and US News and World Report listing of Top Pathologists of America since 2008.

Hooman Rashidi

Dr. Rashidi is a physician scientist, inventor of several established and validated Machine learning Platforms (e.g. MILO Auto-ML, STNG, etc.) and a prolific author. He is the Associate Dean of AI in Medicine at the University of Pittsburgh SOM, Professor & Executive Vice Chair of Computational Pathology and the Executive Director of CPACE (Computational Pathology & Ai Center of Excellence, a joint UPitt/UPMC venture). In light of his extensive background and experience in the machine learning realm, he continues to create innovative new tools and resources along with publishing best practice guidelines that improve clinical practice, research, and education.
He is also a committed educator with numerous teaching awards and well-established educational Apps. His efforts in the AI-ML & digital space are internationally recognized, as evidenced by his numerous continuous invited talks, editorial & reviewer roles, numerous published key invited review articles & his continued national committee roles.

Jana Lipkova

Jana’s research lab, OctoPath, stands at the crossroads of medical exploration and technological innovation within the Department of Pathology at the University of California, Irvine. The lab focuses on developing AI methods to address crucial needs in oncology, organ transplant, immunology, and other disease areas, leveraging multimodal data from histology, radiology, genomics, and beyond. Jana recently completed her postdoc training with Prof. Faisal Mahmood at Harvard Medical School, Department of Pathology. She earned her PhD from the Technical University in Munich, where her work centered on computer-aided medical procedures in radiology. For further insights into our ongoing work, visit http://octopath.org.

Mark Gustavson

Mark Gustavson is in Translational Medicine Oncology at AstraZeneca where he leads biomarker development and translational medicine strategy within the Antibody-Drug Conjugate (ADC) program. Before moving to Translational Medicine, he was part of the Precision Medicine group at AstraZeneca leading development of Companion Diagnostics. Prior to joining AstraZeneca, he was with the Food and Drug Administration (FDA) where he served as both scientific reviewer and member of the Personalized Medicine Group reviewing and developing policy for companion diagnostic devices including digital pathology and next-generation sequencing. Prior to the FDA, he was Vice President of Diagnostics for MetaStat, Inc. developing cutting edge quantitative pathology-based diagnostics; and before MetaStat, he worked with Genoptix and HistoRx developing quantitative pathology technologies and applications (e.g. AQUA Technology). Mark received his Ph.D. in Cancer Biology from Vanderbilt University and did his post-doctoral fellowship under Dr. David Rimm at Yale University.

Mathieu Marella

• Mathieu Marella is originating from south of France where he obtained a Ph.D. in Molecular and Cellular Pharmacology, majoring in neurodegenerative disease. Mathieu investigated the toxic properties of Prion protein aggregates in mouse models.
• Pursue, in San Diego, California, a Post-doctoral fellowship at The Scripps Research Institute to create a gene therapy against Parkinson’s disease, and Leber’s Hereditary Optic Neuropathy.
• Joined the biotech industry world in 2013 first at Halozyme Therapeutics, then Celgene/BMS in 2017. Where he worked as a scientist in a molecular pathology lab focused translational biology and explorative toxicology.
• Currently managing the Molecular Pathology lab at Johnson and Johnson Innovative Medicine since 2020 focusing on Preclinical Safety and providing support across the JnJ therapeutic portfolio.

Laura Dillon

Laura Dillon, Ph.D., is Vice President of Translational Medicine & Bioinformatics at Incendia Therapeutics, a Boston-based biotech focused on targeting immune excluded tumors. She is responsible for designing and implementing the company’s biomarker strategy across preclinical and clinical activities, including the use of traditional and novel imaging and omics technologies and analysis platforms, as well as novel target discovery and validation through the application of bioinformatics approaches to public and proprietary datasets. Dr. Dillon has over 15 years of experience in industry, academia, and government. Prior to joining Incendia, Laura was Director of Pathology Data Strategy at AstraZeneca where she focused on the development of machine learning-based methods to extract information from imaging datasets and the implementation of non-invasive bioimaging techniques to advance the drug development pipeline. Laura has a Ph.D. in Bioinformatics and Genomics from the University of Maryland.

Richard Levenson

Richard Levenson, MD, FCAP, is professor and vice chair for strategic technologies, Department of Pathology and Laboratory Medicine, UC Davis Health. He received his MD at University of Michigan and pathology training at Washington University, followed by a cancer research fellowship at Univ. of Rochester and faculty positions at Duke and Carnegie Mellon. He then joined Cambridge Research & Instrumentation, becoming VP of Research before assuming his present position at UC Davis. He has helped develop multispectral microscopy and small-animal imaging systems and sofware, birefringence microscopy, multiplexed ion-beam imaging (MIBI), and most recently, slide-free as well as enhanced-content microscopy approaches. He is section editor for Archives of Pathology and is on the editorial board of Lab. Invest. and AJP. Regrettably, he also taught pigeons histopathology and radiology. He is a recipient of the 2018 UC Davis Chancellor’s Innovator of the Year award and is a Fellow of SPIE.

Giovanni Lujan

Dr Lujan holds dual board certification in Anatomic and Clinical Pathology, and he is also certified by The American Board of Artificial Intelligence in Medicine. His clinical expertise is in Gastrointestinal Pathology. He completed a Surgical Pathology fellowship at The Johns Hopkins Medical Institutions after graduating from the Pathology residency program at The University of Texas Southwestern Medical Center. Dr Lujan has held previous academic appointments at The Johns Hopkins University School of Medicine and The University of Texas Southwestern Medical School. He was director of a GI fellowship program for several years.

Daniel G. Rudmann

Dr. Dan Rudmann is an ACVP board certified veterinary toxicologic pathologist with almost 25 years of experience in the pharmaceutical and biotechnology industries. He is presently Senior Director of Digital Pathology at Charles River Laboratories. In this role, Dr. Rudmann is leading the digital transformation for pathology at Charles River, a company that employs over 150 pathologists. His scientific interests include the application of Deep Learning artificial intelligence models to toxicologic and diagnostic pathology and he leads a global working group investigating AI applications at CRL. Dr. Rudmann publishes and speaks frequently on Digital Pathology topics and is working with the CRL team to collaborate broadly across the industry in support of pathology digitalization.

Zoltan Laszik

Dr. Zoltan G. Laszik is a surgical pathologist with special interest in renal pathology who published extensively on various aspects of native and transplant kidney diseases. As the director of digital pathology he led the efforts to implement a fully digital workflow for primary diagnosis at UCSF that was launched in March, 2020. His research laboratory uses novel technologies to study the cellular composition of tissues, in situ. He has developed and optimized a number of quantitative highly multiplexed immunofluorescent assays combined with whole slide digital imaging, tissue flow cytometry and image analysis.

Chih-Hong Wang

Chih-Hong Wang, Operations Manager, Pathology at Regeneron Pharmaceuticals, Inc., brings over a decade of expertise in histology, pathology, and preclinical drug development. With a PhD in Molecular and Cellular Pathology from UNC-Chapel Hill (2010) and postdoctoral training at UC San Diego, he specializes in cardiovascular diseases and oncology, with 17 publications to his name. His skills span advanced imaging analysis, biomarker research, and digital pathology, honed through roles at Tulane University, UMICH, and TrueBinding Inc. Dr. Wang excels in pathology teams, integrating cutting-edge technology, and fostering collaboration. He leverages HALO-AI and machine learning to enhance biomarker and imaging analysis, delivering precise, impactful results. Motivated by a commitment to support scientists and pathologists, he drives innovation in critical research projects, ensuring excellence in study outcomes and scientific advancement.

Evita Sadimin

Evita Sadimin, MD is an Associate Professor of Pathology, and Chief of the Division of Pathology Informatics and Data Science at City of Hope. She completed her Fellowship in Pathology Informatics and her residency in Anatomic and Clinical Pathology, serving as Chief Resident, at Rutgers Robert Wood Johnson Medical School. She then completed a Fellowship in Genitourinary Pathology at the Johns Hopkins Medical Institutions. After her Genitourinary Pathology fellowship, she joined the faculty of the Department of Pathology and Laboratory Medicine at the Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School. Her experiences include working with informatics, LIS and IT teams in establishing digital pathology services, supporting daily informatics activities in clinical and research efforts, improving and expanding clinical data warehouse, and supporting biorepository services. In addition, her clinical work focuses on urologic oncology pathology.

Hatef Mehrabian

I am a Research Scientist in the Non-clinical Safety and Pathobiology department at Gilead Sciences. My research focuses on developing machine learning and deep learning tools for the automated analysis of digital pathology images (IHC, mIF, H&E). Prior to joining Gilead Sciences in 2020, I served as a post-doctoral fellow at the University of California, San Francisco (UCSF), where my work centered on developing imaging and image analysis tools (machine learning and AI) for cancer and musculoskeletal diseases. Additionally, I was a post-doctoral fellow at Sunnybrook Research Institute in Toronto, Canada, from 2014 to 2016, conducting research on new MRI contrast mechanisms for cancer diagnosis. I earned my Ph.D. from the Medical Biophysics department at the University of Toronto in 2014, with thesis on developing data-driven machine learning techniques for unmixing spatiotemporal signals in cancer MRI.

Sripad Ram

Sripad Ram heads the digital pathology and image analysis group at Pfizer which supports histopathology image analysis for preclinical and early-stage clinical programs across the Pfizer portfolio. His research interests include digital scoring of IHC biomarkers for clinical specimens and AI/ML algorithm development for whole-slide image analysis. He received his PhD in Bioengineering from UT Southwestern Medical Center and continued his postdoctoral research at the same institution as a National Multiple Sclerosis Society Postdoctoral Fellow where he developed novel microscopy tools to image macromolecule transcytosis across the blood-brain barrier at the single molecule level. He continued is postdoctoral work in the field of cancer therapeutics and antibody engineering where he investigated the trafficking mechanisms of trastuzumab in breast cancer cells. Prior to joining Pfizer, he worked at Carl Zeiss Inc as a microscopy systems specialist.

Harsh Thaker

Harsh Thaker is the Director of Anatomic Pathology and Vice Chair for Digital & Integrative Pathology at the University of Texas Medical Branch, Galveston, TX. At UTMB he led one of the earliest and most successful implementations of Digital Pathology in the US, with 100% digital primary diagnosis of surgical pathology and routine incorporation of AI-assistance tools for diagnosis of prostate and breast cancer. He is now collaborating with colleagues in Clinical Pathology, Radiology and Informatics to develop and implement AI-driven integrative diagnostic reports to guide patient management and deliver greater value to the health system. Dr. Thaker is board-certified in Anatomic Pathology and Clinical Informatics. He holds an MD from India and a PhD from Yale University.

Brittany Dugger

Dr. Dugger has led, enabled, and enhanced many cross-disciplinary projects, resulting in more than 75 peer-reviewed manuscripts and numerous private, state, and federally funded grants. Dr. Dugger earned her Bachelor of Science from Michigan State University and PhD from Mayo Clinic. She completed a postdoctoral fellowship and was an independent staff scientist at the Banner Sun Health Research Institute. In 2015, she became neuropathology core leader for academic/drug discovery groups at the Institute of Neurodegenerative Diseases, University of California San Francisco. Currently, she is an associate professor of Pathology and Laboratory Medicine at University of California, Davis (UCD), neuropathology core co-leader of the UCD-Alzheimers Disease Research Center (ADRC), co-leader of UCD School of Medicine Machine Learning Working Group, and department Liaison for the Women in Medical and Health Sciences. Dr. Dugger is involved in many national endeavors, including the College of American Pathologists Neuropathology and ADRC Neuropathology Core Steering Committees.

Erio Barale-Thomas

Vision: Improving the workflow of toxicologic pathology by increasing standardization in histology, implementing digital pathology, and bringing quantification to pathology evaluation.

Biosketch: Erio graduated from the Veterinary School of Lyon, France, in 1989 and holds a national degree in toxicologic pathology. Since 2003 he works for Janssen Pharmaceutica in Beerse, Belgium. Throughout his career he was interested in special stains and special techniques, and in mentoring young colleagues undergoing their veterinary pathology residency.

He currently leads the digital pathology efforts in the histology and pathology departments, for both the infrastructure/platform and the scientific applications; he also liaises with IT (for optimizing platform design) and other scientific departments/therapeutic areas (for synergy in bringing tools on the platform).

He is also a strong advocate of cooperation among international toxicologic pathology societies and is very involved in the interaction with regulatory bodies. He is a former president of the French Society of Toxicologic Pathology and an active member of the European and North American STP.

Eder Lagemann

Eder Lagemann leads the Global Digital Pathology efforts at KLAS Research. He studied Electronics Technology and Business Management and has worked in various positions in the healthcare industry for the last 18 years. He is passionate about discovering and reporting what is reality and helping to improve patient outcomes through the use of technology.

At KLAS, Eder works closely with key decision makers and influencers throughout the world to understand how vendors are meeting the needs of their clients. He is the author of various global studies covering trending HIT topics.

Fabian Heinemann

Fabian is heading the IT Data Science Chapter and the Central Data Science EMEA I team within Boehringer Ingelheim. The team explores and develops of AI applications for all functions of the company. Prior to his current role, Fabian served as the head of the Biomedical AI lab at Boehringer Ingelheim’s research organization. His team specialized in the development and application of deep learning-based tools for extracting quantitative information from histological sections, specifically for pharmaceutical research Fabian’s experience includes working as a data scientist at Roche and conducting research at research institutes like the Max-Planck Institute for Biochemistry. His educational background is physics, with specializations in biophysics and theoretical physics. Throughout his career, he has conducted research in various fields, ranging from biophysics, life science, material science, optics, to simulations of biological processes, and most recently applied machine learning.

Priti Lal

Dr Lal is Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and director of GU subdivision. Dr Lal’s primary research work is on prostate cancer. She is pathology PI on multiple grants that are focused on developing a deeper understanding of prostate cancer including its 3D morphology, native immune microenvironment, causes of treatment resistance, CAR-T treatment associated changes in tumor immune microenvironment, and development of contemporary AI models for diagnosis and prognosis of prostate cancer. In addition to her research work Dr manages a busy clinical practice and teaches extensively at national and international meetings. She is an active member of the executive committees for USCAP and GUPS and has contributed to the development of national guideline white papers for prostate cancer. Dr Lal finds great joy in mentoring medical students, residents, fellows and post docs and has successfully published with students at each level.

J. Mark Tuthill

J. Mark Tuthill, MD, completed pathology residency and informatics fellowship training at the University of Vermont College of Medicine-Fletcher Allen Health Care, and created the department’s division of pathology informatics. Dr. Tuthill is Division Head of Pathology Informatics at Henry Ford Health System in Detroit. Areas of interest include digital pathology implementation, Internet applications for laboratory services, laboratory information systems, business analytics, electronic health records and informatics training and education. Active in organized medicine, he is an advisor to the ASCP Annual Meeting Steering Committee; Delegate, Wayne Medical Society; Co-director for the API’s Pathology Informatics Summit; and Delegate for CDC’s CLIAC committee. As a charter member of the Association for Pathology Informatics, Dr. Tuthill has worked for the API from its inception serving as president, chair of the membership committee, education committee, and the organization’s original planning group. Dr. Tuthill is the recent recipient of the API’s distinguished service award.

Joshua J. Levy

Dr. Joshua Levy is the Director of Digital Pathology Research at Cedars-Sinai and holds a joint appointment in the Department of Computational Biomedicine. He formerly served as an Assistant Professor of Pathology, Dermatology, and Epidemiology at the Geisel School of Medicine and Dartmouth-Hitchcock Medical Center. Dr. Levy’s research focuses on integrating AI and biostatistics in anatomic pathology, developing computational methods for histopathology, cytopathology, text and image processing, and analyzing spatial molecular variations in tumors through spatial genomics technologies, amongst numerous other application areas. His academic path commenced with a physics degree from the University of California, Berkeley, followed by computational biology and software development roles at Lawrence Berkeley National Laboratories and in industry, leading to a doctorate in quantitative biomedical sciences from Dartmouth College Geisel School of Medicine. At Cedars-Sinai, his goal is to establish a nationally recognized digital pathology research program and create student recruitment pathways to bring new talent into the field. Dr. Levy’s mentorship efforts are highlighted by the establishment of a national internship program, through which he has guided over 150 students from diverse educational backgrounds. Dr. Levy also holds various consulting roles at the Biomedical National Elemental Imaging Resource and Veteran Affairs.

Albert Juan Ramón

Albert Juan Ramon, PhD, a Principal Scientist at Johnson and Johnson (J&J) Data Sciences, specializes in computer vision and artificial intelligence. Holding a B. Eng from the Polytechnic University of Catalonia and a Master’s and PhD in Electrical and Computer Engineering from the Illinois Institute of Technology (IIT), his research at IIT focused on AI algorithms in nuclear cardiac imaging.

Currently leading histopathology efforts at J&J, he focuses on developing AI imaging algorithms for various therapeutic areas. His notable contribution is the development of an AI-powered biomarker test to predict the likelihood that a patient’s tumor harbors actionable genetic alterations from H&E images. This tool was the first image-based tool deployed on a J&J clinical trial to screen patients prior to genetic testing, resulting in enhanced trial efficiency and a substantial reduction in genetic testing costs by approximately 30%.

Corey Arnold

Prof Arnold is the Vice Chair of Research in the UCLA Department of Radiological Sciences and holds joint appointments in the Departments of Pathology & Laboratory Medicine, Electrical & Computer Engineering, and Bioengineering. He leads the Computational Diagnostics Lab, a team that uses machine learning to improve healthcare. He completed his undergraduate training at the University of Wisconsin, Madison and earned his PhD at UCLA.

Tamara Jamaspishvili

Dr Jamaspishvili (MD, PhD) is a research pathologist, assistant professor, and Director of the Pathology Research Core & Digital Pathology lab at SUNY Upstate Medical University. Her translational research focuses on developing and validating tissue-based prognostic and predictive biomarkers and models to improve disease prognostication and management of cancer patients. Dr Jamaspishvili and her collaborative multi-disciplinary group of researchers have developed innovative strategies to advance biomarker assessment using quantitative computational pathology and artificial intelligence (AI) that would impact cancer research and, ultimately, clinical practice in the future.

Arvind Rao

Arvind Rao is a Professor in the Department of Computational Medicine and Bioinformatics at the University of Michigan. His group uses image analysis and machine learning methods to link image-derived phenotypes with genetic data, across biological scale (i.e. single cell, tissue and radiology data). Such methods have found application in radiogenomics, drug repurposing based on phenotypic screens and spatial profiling in tissue, as well as in spatial transcriptomics. Arvind received his PhD in Electrical Engineering and Bioinformatics from the University of Michigan, specializing in transcriptional genomics, and was a Lane Postdoctoral Fellow at Carnegie Mellon University, specializing in bioimage informatics.

Shahla Masood

Dr. Shahla Masood is a Persian born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine Jacksonville. She is the Director of the Cytopathology and Breast Pathology Fellowship Training Programs, as well as the Medical Director of UF Health Breast Center, Chair of the Cancer Committee, and Interim Director of UF Health Jacksonville Cancer Program. As an internationally recognized expert in breast cancer diagnosis and prognosis, Dr. Masood has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research, and education. She is the founder and first Editor-in-Chief of The Breast Journal, the founder and past president of the International Society of Breast Pathology, the Director of the Annual Multidisciplinary Symposium on Breast Disease, and The Breast Cancer Public Forum. Dr. Masood is a patient advocate, a partner in community affairs and an accomplished artist and gourmet chef. She is the wife of her talented and loving husband, Dr. Ahmad Kasraeian and a mother of two accomplished physicians, Dr. Ali Kasraeian, an urologist, and Dr. Sina Kasraeian, an orthopedic surgeon, as well as a caring grandmother to six beautiful grandchildren.

Sunil Singhal

A computer scientist by training, Sunil Singhal is an entrepreneur, product builder and management consultant. He is a broad thinker who excels at finding elegant collaborative solutions to problems that enhance human experience. He has over 30 years of c-suite management consulting experience in multiple industries.

Sunil serves as Principal Consultant at Synergess. Prior to this he served as Chief of Digital Pathology Transformation at Baylor College of Medicine. He has experience in formulating and implementing Digital Pathology strategy to support clinical, research and education missions. He has managed successful implementation of digital pathology programs at The Ohio State University, West Virginia University, Baylor College of Medicine, and The University of Alabama at Birmingham. He is interested in digital pathology workflow, image analysis, data analytics and computational pathology.

Sunil has bachelor’s degree in Electronics and Communication Engineering from Indian Institute of Technology, Roorkee, India, and a master’s degree in Electronics Engineering from Netherlands.

Chao-Hui Huang

Chih-Hong Wang is currently the Operations Manager of Pathology at Regeneron Pharmaceuticals, Inc. He earned his PhD in Molecular and Cellular Pathology from the University of North Carolina at Chapel Hill in 2010 and completed his postdoctoral fellowship at the University of California San Diego. With over a decade of experience in histology and pathology studies, his research primarily focuses on cardiovascular diseases and hematology. He has published 17 papers in these fields. Before joining Regeneron in 2022, he held faculty positions in the Department of Physiology & Hypertension and Kidney Center at Tulane University, and the Department of Internal Medicine, Division of Nephropathy at UMICH. He later served as a principal scientist of the histopathology team at TrueBinding Inc. He is driven by the mission to assist scientists and pathologists in achieving fulfillment and a sense of belonging in their study projects. He utilizes digital pathology to foster collaboration on significant projects in preclinical drug development studies.

Natasha Darras

Mustafa Yousif

Dr. Mustafa Yousif serves as an Assistant Professor and the Director of Digital Pathology at the University of Michigan in Ann Arbor, MI, USA. He earned his medical degree from the University of Al-Mustansiriyah in Baghdad, Iraq, and completed his anatomical and clinical pathology residency at Wake Forest University. Following this, Dr. Yousif undertook a fellowship in Gynecologic and Breast Pathology at the University of Pittsburgh Medical Center, as well as a fellowship in Pathology Informatics at the University of Michigan’s Department of Pathology Informatics. He possesses extensive knowledge and a keen interest in pathology informatics and digital pathology. His research primarily focuses on digital pathology and artificial intelligence, with a particular emphasis on computer vision and image analysis, in addition to his work in gynecologic and breast pathology.

Peter Gershkovich

After completing a fellowship in Medical Informatics funded by the National Library of Medicine in the early 2000s, I have spent nearly two decades working to improve diagnostic and laboratory processes in Pathology at Yale. My efforts have led to the transition of pathology systems towards more agile and modular components, reflecting the principles of DevSecOps and enhancing operational efficiency. My work has been focused on integrating engineering principles into clinical operations within the department, as outlined in my publications that address functionality gaps in laboratory information systems. Additionally, I led the development of a web-based platform for the analysis of tumor DNA sequencing, aiming to advance precision medicine. My team developed numerous other systems that constitute REALM (Rapidly Evolving Agile Laboratory Modules), setting new standards for pathology diagnostics and research at Yale. Currently, my work centers on improving operational efficiency, digital pathology, and exploring the potential of artificial intelligence in our field.

David Gutman

David Gutman, MD, PhD is an Associate Professor in the Department of Pathology and Clinical Medicine at Emory University School of Medicine. Dr. Gutman joined the faculty at Emory in 2000, after completing his Psychiatry Residency.  His group develops and maintains open source tools to support digital pathology including the Digital Slide Archive (DSA) package and HistomicsTK.  He has broad expertise in medical imaging, having helped develop the International Skin Imaging Archive (ISIC), the Cancer Digital Slide Archive which contains 25,000+ whole slide images, and is also adapting these tools for neuropathology

Orly Ardon

Orly Ardon is the Director of Digital Pathology Operations and an assistant member at the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center.

She has expertise in microbiology, molecular, and digital pathology. Orly completed the degrees of BSc, MSc, and Ph.D. in Microbiology at the Hebrew University of Jerusalem, and an Executive MBA from the University of Utah. Her postdoctoral training was in cell biology and virology at the University of Utah. Before joining MSKCC, Orly was heading the development of novel computer assisted diagnostic tools and the expansion of digital pathology collaborative initiatives at ARUP Laboratories in Salt Lake City, Utah.

Dr. Ardon career focuses on diagnostic test advancements and laboratory innovation. Her work in digital pathology is centered on operational aspects of the digital technologies and the clinical implementation of laboratory automation. Her interests also include process improvements and healthcare economics.

Fangyao Hu

Fangyao is the leading computational scientist within the Genentech Safety Assessment digital pathology group. He earned his Ph.D. in Biomedical Engineering from Duke University. At Genentech, he leads a team focused on applying machine learning and deep learning to enhance the digital pathology workflow in toxicologic pathology. His innovative leadership in computational methods has significantly advanced the extraction of reliable, quantitative data from pathology images. These advancements not only enhance analytical insights but also promote comprehensive cross-study comparisons and the development of predictive models for safety assessments.

William Jeck

Dr. William Jeck received his dual degree from the University of North Carolina in Chapel Hill with a PhD in genetics and molecular biology from the laboratory of Dr. Norman Sharpless. Dr. Jeck training in Anatomic Pathology at Massachusetts General Hospital and received a Fellowship in gastrointestinal pathology from Brigham and Women’s Hospital. As an assistant professor at Duke University School of Medicine he signs out gastrointestinal, liver, bone and soft tissue, and molecular pathology and plays a key role developing system architecture for digital pathology, including special projects implementing and validating AI systems within existing viewers. Dr. Jeck’s research interests focus on the intersection between molecular and digital pathology, as well as development of tools to implement AI to improve the practice of surgical pathology.

Alina Ainbinder

Life sciences professional with over a decade of experience in digital pathology, image analysis, and biomarker discovery. I hold a B.Sc. in Biotechnology Engineering from Ort Braude College in Israel and a Ph.D. in Pharmacology from the University of Rochester.
I began my career as a Scientist at the Broad Institute, studying genetic perturbations in type 2 diabetes and developing high-content microscopy assays for large-scale cellular profiling. I then worked at Ultivue Inc., focusing on product development and whole-slide image analysis tool development.
Currently, I am a Research Associate Director at Takeda Pharmaceuticals in Cambridge, MA, where I lead digital pathology initiatives for oncology drug development. My work includes developing AI-driven image analysis capabilities, overseeing vendor selection for spatial proteomics and digital pathology, and building cloud-based infrastructure for digital pathology. I focus on integrating advanced imaging technologies into clinical trials, bridging translational research with clinical applications to enhance biomarker discovery.

Erick Lin

Rick Torres

Sam Seymour

Sam Seymour, Director of Product at Paige, oversees the Paige Platform, and its integration of AI into clinical workflow. With a genomics degree from Vassar College, Sam began his career in academic and industry research, delving into enzyme kinetics and pharmacokinetics. Transitioning into healthcare technology through a Masters degree from UC San Francisco and UC Berkeley, Sam is now dedicated to the intersection of AI and clinical workflow. His mission is to facilitate effective collaboration between humans and AI to enhance healthcare economics and achieve better patient outcomes.

W. Dean Wallace

Dr. W. Dean Wallace is a Professor of Pathology and the Director of the Translational Pathology Core at the Keck School of Medicine of USC. Dr. Wallace’s experience with digital pathology and informatics goes back more than fifteen years during his involvement in establishing the California Telepathology Network and the development of the integrated radiology-pathology reporting platform at his previous institution, UCLA. As a recognized expert in the field, Dr. Wallace has been invited to speak at many national and international meetings on the field of digital pathology. His areas of investigative interest include studying the effective deployment of digital pathology systems in the clinical setting.

Chaith Kondragunta

Chaith Kondragunta is the CEO of AIRAMatrix Pvt. Ltd based in Mumbai, India. AIRAMatrix provides AI based solutions to the Life Sciences industry. The company’s solutions help improve workflow efficiency and help increase accuracy in pharmaceutical drug discovery and development as well as in healthcare diagnostics, prognostics and predictions. Chaith has extensive leadership experience with AI and Data analytics platform companies. He has also served in leadership roles in corporate strategy and management consulting in the US and Europe. He frequently writes and speaks on AI and Data Analytics for several media outlets including The Economist Group, CNBC and Bloomberg TV.

Nitin Singhal

Nitin is a technology professional with a track record of building AI-powered repertoire of medical imaging products. At AIRA Matrix he leads the strategic vision for Project and Portfolio management.  He focuses on designing AI products and solutions to aid predictive diagnostics . His areas of expertise include medical image analysis, machine learning and deep learning, computer vision, computer-aided diagnosis, GPU computing, mobile computational photography, and digital image management. Nitin has authored 50+ publications in international journals and conferences and has 10 granted patents to this name.

Uttara Joshi

Uttara is a surgical pathologist who has spearheaded the development of an integrated digital solution for pathology.At AIRA Matrix, her experiences in healthcare and technology provide leadership for the entire scale of Artificial Intelligence based solutions offered for the cancer care pathway.

Akash Parvatikar

Akash received his PhD in Computational Biology from the Joint Carnegie-Mellon and University of Pittsburgh School of Medicine. He specializes in biomedical imaging informatics and computational and systems pathology. Akash investigates the intrinsic characteristics of biomedical images at multi-scale resolutions using statistical modeling, computer vision, machine learning, and graph-based deep learning techniques. At HistoWiz, Akash develops tools to ensure quality images, accelerates histopathology, and develops AI tools for preclinical researchers across academic, biotech, and pharmaceutical domains. 

Trevor McKee

Dr. Trevor McKee has a PhD in Bioengineering from MIT, and has spent the last two and a half decades applying computer vision techniques to the analysis of biomedical images. He spent 14 years as director of the STTARR Innovation Centre Image Analysis Core, where he led a team of programmers to develop quantitative analysis methods of spatial biology datasets spanning brightfield, multiplex and imaging mass cytometry images. He has over 50 peer-reviewed publications in these fields, and is a part of the JEDIS council – Joint Effort to Develop Immunofluorescence Standards – working to move modern multiplex staining methods to routine clinical use. He is currently the Chief Technology Officer at Pathomics.ai, an image analysis company driven to transform the landscape of spatial biology by delivering product solutions and services which demystify complex imaging data.

Mark Frushone